NCT02166489

Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease

Evaluation the Effect of Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Royan Institute · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).

Detailed description

The investigators will assess the 18-month safety and potential efficacy of autologous MSCs as therapy for ADPKD. A total of 6 patients with ADPKD IV injection of high doses 2×106 of autologous mesenchymal stem cells / kg their weight, which will be derived from biopsies of their bone marrow. Assessments will be made at 1, 3, 6, 12 and 18 months after cell injection. Changes in GFR rate were evaluated by scan isotope.

Conditions

• Chronic Renal Failure
• Polycystic Kidney Disease

Interventions

Type	Name	Description
BIOLOGICAL	Intravenous injection autologous mesenchymal stem cells	Intravenous injection of mesenchymal stem cell in patients with PKD

Timeline

• Start date: 2014-03-01
• Primary completion: 2015-12-01
• Completion: 2016-01-01
• First posted: 2014-06-18
• Last updated: 2016-01-05

Locations

1 site across 1 country: Iran